REG - Theracryf PLC - Result of General Meeting

TheracryfAnnouncement

07/03/2025 12:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250307:nRSG8573Za&default-theme=true

RNS Number : 8573Z  Theracryf PLC  07 March 2025

TheraCryf plc

("TheraCryf", the "Company" or the "Group")

Result of General Meeting

and

Total Voting Rights

Alderley Park, UK - 7 March 2025: TheraCryf plc (AIM: TCF), the clinical stage
drug development company focussing on oncology and neuropsychiatry,
announces that at the General Meeting held today at Mereside - No. 11 Lecture
Theatre, Alderley Park, Alderley Edge, Macclesfield, SK10 4TG, all resolutions
were duly passed.

 

Details of the proxy voting instructions lodged prior to the General Meeting
for each Resolution are shown on the Company's website.

 

Total Voting Rights

 

The 1,620,315,527 New Ordinary Shares to be issued pursuant to the Fundraising
are expected to be admitted to trading on AIM at 8 a.m. on 11 March 2025.
Following this Second Admission, the total number of Ordinary Shares in issue
will be 2,129,622,422, with no shares held in treasury. This is the figure
that may be used by shareholders as the denominator for the calculations by
which they will determine if they are required to notify their interest in, or
a change to their interest in the Company under the FCA's Disclosure Guidance
and Transparency Rules.

Unless otherwise defined herein, terms used in this announcement have the
meaning given to them in the £4.25m Placing & Subscription and Notice of
GM announcement dated 19 February 2025.

Enquiries

 TheraCryf plc                                               +44 (0)1625 315 090

Dr Alastair Smith, Chair
 enquiries@theracryf.com

 Dr Huw Jones, CEO

Toni Hänninen, CFO

 Dr Helen Kuhlman, CBO
 Cavendish Capital Markets (NOMAD & Joint Broker)            +44 (0)20 7220 0500
 Geoff Nash / Teddy Whiley / Rory Sale (Corporate Finance)

Nigel Birks / Harriet Ward (ECM)
 Turner Pope Investments (Joint Broker)                      +44 (0)20 3657 0050

 James Pope / Andy Thacker
 Vigo Consulting                                             +44 (0)20 7390 0231

                             theracryf@vigoconsulting.com
 Rozi Morris

About TheraCryf plc

TheraCryf is the clinical stage drug development company focussing on oncology
and neuropsychiatry. The Company has a broad clinical and preclinical pipeline
in indications including glioblastoma* neurodevelopmental disorders,
addiction, anxiety and narcolepsy [*orphan indication].

The Company's strategy is to generate compelling data sets to preclinical
and/or clinical proof of concept and partner its clinical programmes with
mid-size to large pharma for larger trials and commercialisation. As well as a
number of industry partnerships with companies, including Stalicla SA, in
neurodevelopmental disorders.  The Company has sourced know how for
programmes from companies such as Shire (now Takeda).

TheraCryf has worked with and has ongoing collaborations with major
universities and hospitals such as the University of Manchester, La Sapienza
(Università di Roma), the Erasmus Medical Centre, Rotterdam, Kings College
London and the University of Michigan.

The Company has its headquarters and registered office at Alderley
Park, Cheshire. It is quoted on AIM in London and trades under the ticker
symbol TCF. 

For further information, please visit: www.theracryf.com
(file:///C%3A/Users/MToyneSewell/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/XN44CN5I/www.theracryf.com)
.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROMUPUGUWUPAGPM